HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $17.15, but opened at $17.59. HUTCHMED shares last traded at $17.53, with a volume of 25,921 shares changing hands.
Analysts Set New Price Targets
HCM has been the topic of a number of recent research reports. Wall Street Zen raised shares of HUTCHMED from a "buy" rating to a "strong-buy" rating in a report on Friday, June 6th. HSBC cut HUTCHMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th.
Get Our Latest Stock Analysis on HCM
HUTCHMED Trading Up 3.3%
The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The stock's 50 day moving average is $14.25 and its 200 day moving average is $14.78.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in HCM. Barclays PLC grew its position in HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after buying an additional 2,255 shares during the last quarter. Public Employees Retirement System of Ohio grew its position in HUTCHMED by 49.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock worth $39,000 after buying an additional 899 shares during the last quarter. Summit Trail Advisors LLC grew its position in HUTCHMED by 14.4% in the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock worth $189,000 after buying an additional 1,647 shares during the last quarter. OLD Mission Capital LLC acquired a new position in HUTCHMED in the fourth quarter worth approximately $230,000. Finally, Marshall Wace LLP acquired a new position in HUTCHMED in the fourth quarter worth approximately $261,000. Institutional investors and hedge funds own 8.82% of the company's stock.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Further Reading
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
